Chemsex-associated drug use amongst men and gender-diverse people having sex with men in the UK: findings from an online community survey, 2024

A 2024 UK online survey of 2,758 men and gender-diverse people who have sex with men found that the 8% who reported chemsex-associated drug use exhibited significantly higher sexual risk behaviors, poorer mental wellbeing, and greater engagement with sexual health services compared to non-users, highlighting the critical role of these services in providing harm reduction support.

The Gist

Imagine a large, digital town square where thousands of men and gender-diverse people who have sex with men gather to share their stories. In late 2024, researchers set up a booth in this town square to ask a very specific question: "Who is using party drugs to spice up their sex life, and how are they doing?"

This study is like a health check-up for a specific group within that community. Here is the story of what they found, explained simply.

The Main Characters: "Chemsex"

First, let's define the term Chemsex. Think of it like adding a very strong, potent spice to a meal. Some people use specific drugs (like crystal meth, mephedrone, or GHB/GBL) before or during sex to make the experience last longer, feel more intense, or lower their inhibitions.

The researchers wanted to know: How many people are doing this? And more importantly, is this "spice" making their lives better or causing them trouble?

The Survey: A Snapshot of the Crowd

The researchers asked 2,758 people in the UK to fill out an online survey. It was like taking a giant photo of the community at a specific moment in time.

The Big Numbers:

• The "Ever" Group: About 15% of the people said, "Yes, I've tried this at some point in my life."
• The "Recent" Group: About 8% (roughly 1 in 12) said, "I've done this in the last year."

So, while it's not something everyone is doing, it's a significant minority.

The Two Groups: A Tale of Two Cities

The researchers split the crowd into two groups: those who used these drugs recently and those who didn't. They then compared their lives, like comparing two different neighborhoods.

1. The "Recent Users" Neighborhood:
This group was more likely to be:

• Gay and living in London (the big city).
• Living with HIV (about 1 in 4 of this group).
• Struggling financially (less "comfortable" with money).
• Feeling down: They reported more mental health struggles and lower life satisfaction. It's like they were carrying a heavier backpack than the other group.

2. The "Non-Users" Neighborhood:
This group generally reported:

• Better financial comfort.
• Higher life satisfaction.
• Fewer mental health limitations.

The Risk Factor: Driving Without a Seatbelt

The study found a clear link between using these drugs and taking bigger risks.

• The Analogy: Imagine driving a car. The "Non-Users" mostly drive with seatbelts on and follow the speed limits. The "Recent Users" were much more likely to be driving fast, without seatbelts, and on dangerous roads.
• The Reality: The drug-using group had a much higher rate of sexual risks (like having many partners without condoms or meeting partners in risky places). This increases the chance of catching or spreading infections like HIV or syphilis.

The Silver Lining: They Are Showing Up for Help

Here is the most important part of the story. Even though this group was taking more risks and feeling worse emotionally, they were actually visiting doctors and sexual health clinics more often.

• 81% of the drug users had visited a sexual health clinic in the last year, compared to only 57% of the non-users.
• They were also more likely to be using PrEP (a pill that prevents HIV).

What does this mean?
It's like a group of people who are running a marathon in the rain (taking risks) but are also the ones stopping at the aid stations to get water and bandages (seeking help). They know they are in a risky situation and are trying to protect themselves.

The Takeaway: What Should We Do?

The researchers concluded that while this group is small, they are the ones who need the most support.

1. Don't Shun Them: Because these people are already visiting sexual health clinics, those clinics are the perfect place to offer help. Instead of just testing for diseases, doctors should gently ask, "Are you using drugs to help with your sex life? We have resources to help you stay safe."
2. Fix the Backpack: The study showed that drug use is often tied to mental health struggles and loneliness. You can't just treat the drug use; you have to help with the sadness and stress that might be driving it.
3. City vs. Country: The problem is biggest in London, but it exists everywhere. We need to make sure help is available in small towns, not just big cities.

In a Nutshell

This study tells us that a small group of people in the UK are using party drugs to enhance their sex lives. This habit is linked to higher risks of infection and lower happiness. However, the good news is that these people are already showing up at clinics. The solution isn't to push them away, but to make those clinics a friendly, non-judgmental place where they can get help for both their sexual health and their emotional well-being.

Technical Summary

1. Problem Statement

Chemsex is defined as the use of specific psychoactive drugs (primarily GHB/GBL, crystal methamphetamine, and mephedrone) to facilitate, enhance, or disinhibit sexual activity. While not all drug use in this context is inherently problematic, it is strongly associated with:

• Increased sexual risk-taking (e.g., condomless anal sex, multiple partners).
• Higher transmission risks for Sexually Transmitted Infections (STIs) and Blood-Borne Viruses (BBVs), including HIV.
• Broader harms such as substance dependence, sexual assault, and lifestyle disruptions (e.g., job loss).
• Poorer mental health and wellbeing outcomes.

Despite the known risks, there is a need for up-to-date data on the prevalence and characteristics of chemsex use in the UK, particularly following the disruptions caused by the COVID-19 pandemic. This study aims to characterize the demographic, behavioral, and wellbeing profiles of men and gender-diverse people having sex with men (GBMSM) who engage in chemsex to inform targeted harm reduction and public health interventions.

2. Methodology

Study Design & Population:

• Survey: The study utilized data from the RiiSH 2024 ("Reducing inequalities in Sexual Health") survey, an annual online cross-sectional study.
• Recruitment: Participants were recruited via social networking sites and geospatial dating apps between November 18 and December 11, 2024.
• Sample: 2,758 UK-resident participants (men and gender-diverse people assigned male at birth) aged ≥16 who reported sex with a man or non-binary AMAB person in the last year.
• Ethics: Approved by the UKHSA Research and Ethics Governance Group (REGG); informed consent was obtained online.

Data Collection & Definitions:

• Chemsex Definition: Participants were asked about the use of crystal meth, mephedrone, or GHB/GBL. "Chemsex-associated drug use" was defined as use within the last year.
• Sexual Risk Composite: A composite measure was created for the previous 3–4 months, including:
  • Bacterial STI diagnosis (chlamydia, gonorrhoea, syphilis).
  • ≥5 male condomless anal sex (CAS) partners.
  • Meeting partners via sex-on-premises venues, public sex environments, or private sex parties.
  • PrEP use in the last year.
• Wellbeing Metrics: Assessed using UK Office for National Statistics (ONS) indicators, including life satisfaction and the presence of long-term limiting physical or mental health conditions.
• Statistical Analysis: Differences between those reporting chemsex use and those who did not were analyzed using Pearson's chi-squared test. Regression modeling was excluded due to small subgroup sizes.

3. Key Contributions

• Post-Pandemic Baseline: Provides the first major UK-wide community-based prevalence estimates of chemsex use in 2024, offering a post-pandemic benchmark to compare against pre-2020 data.
• Intersectional Vulnerability: Highlights the specific intersection of chemsex use with mental health limitations, financial insecurity, and HIV status.
• Service Engagement: Quantifies the high engagement of this specific demographic with Sexual Health Services (SHS), reinforcing the role of SHS as a critical entry point for harm reduction referrals.
• Geographic Distribution: Confirms a significant concentration of use in London while demonstrating that the phenomenon exists across the UK.

4. Key Results

Prevalence:

• Lifetime: 15% (408/2,758) reported ever using chemsex-associated drugs.
• Recent Use: 8% (218/2,758) reported use in the last year.
• Intensity: Among those using in the last 3–4 months, 65% reported using drugs in at least half of their sexual encounters.
• Injection: 4% of the total sample reported ever injecting non-prescribed drugs; 41% of these injectors did so in the last 3–4 months.

Demographic & Socioeconomic Characteristics (Chemsex Users vs. Non-Users):

• Sexual Orientation: Higher proportion identified as gay (87% vs. 80%).
• Location: Significantly higher residence in London (47% vs. 26%).
• HIV Status: Higher prevalence of living with HIV (27% vs. 10%).
• Financial Status: Lower proportion reported being financially comfortable (32% vs. 46%).
• Mental Health: Higher rates of long-term limiting mental health conditions (36% vs. 24%) and low life satisfaction (36% vs. 20%).

Behavioral Outcomes:

• Sexual Risk: 85% of chemsex users met the composite sexual risk criteria, compared to 61% of non-users ($p<0.001$).
• Service Engagement: 81% of chemsex users attended a Sexual Health Service (SHS) in the last year, compared to 57% of non-users ($p<0.001$).
• PrEP Use: Among HIV-negative/unknown status participants, 78% of chemsex users reported PrEP use vs. 49% of non-users.
• Alcohol: Higher frequency of sex under the influence of alcohol (17% vs. 11%).

5. Significance and Implications

Public Health Impact:
The study confirms that while chemsex use affects a minority (8%) of the GBMSM community, this group carries a disproportionate burden of sexual risk and poor wellbeing. The findings suggest that chemsex use is not a transient post-pandemic phenomenon but remains a persistent public health issue with patterns consistent with pre-2020 data.

Clinical & Policy Recommendations:

• SHS as a Gateway: The high attendance at Sexual Health Services by chemsex users indicates that these clinics are the optimal setting for identifying and referring individuals to harm reduction and psychosocial support.
• Holistic Care: Interventions must move beyond sexual health to address mental health, financial instability, and substance dependence simultaneously.
• Stigma Reduction: Services must be culturally competent and non-stigmatizing. Traditional drug misuse services are often avoided; integrating support into sexual health settings is preferred.
• Geographic Equity: While London has high prevalence, resources and infrastructure must be strengthened across the entire UK to support rural and non-urban populations.
• Digital Delivery: As sexual health services shift to digital platforms, there is a risk of losing the ability to triage and refer chemsex users to appropriate face-to-face support.

Limitations:
The study relies on a convenience sample recruited via apps, which may overrepresent those with higher sexual risk behaviors and limit generalizability to marginalized groups (e.g., ethnic minorities, younger populations). The cross-sectional nature prevents establishing causality between drug use and mental health outcomes.